Image Credit: Coherence Neuro
Coherence Neuro has announced $45 million in funding backed by Founders Fund and the OpenAI Startup Fund to develop implantable systems for monitoring and treating cancer. Its proposed SOMA-1 platform would combine recording of electrical activity in the tumor environment with responsive stimulation, initially targeting glioblastoma. The company reported preclinical work in mice using neural recordings to estimate tumor growth and plans to use the funding to advance toward its first chronic human glioblastoma trial. It is also seeking FDA Breakthrough Device designation and expanding its preclinical research into pancreatic cancer. Inventing cancer therapy that learns
The engineering objective is to link continuous electrical sensing with therapeutic stimulation in a closed-loop implant. Coherence’s human study announced in June 2026 at Royal Melbourne Hospital represents an earlier development stage. That study uses CIPHER, a flexible thin-film cortical electrode system, for short-duration recording and stimulation during brain tumor surgery. It evaluates intraoperative safety, performance, and handling rather than chronic cancer treatment. Whether electrical measurements can reliably track human tumor progression and guide effective stimulation remains to be established. The devices remain investigational.